PolarityTE, Inc., a biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates through two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and OsteoTE. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
IPO Year:
Exchange: NASDAQ
Website: polarityte.com
SALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock units covering an additional 256,457 common shares.
SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial UpdatesAt the end of April 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND for SkinTE®. The Company estimates that it may be able to complete enrollment of 100 subjects sometime in the first six mon
SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of control agreements, (2) minimum tender conditions, (3) a sixty-day due diligence period, and (4) satisfacti
SALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced it will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City at 11:00 am, ET, on September 14, 2022. About PolarityTE®PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products. PolarityTE's first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND)
SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE. "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we purs
PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022. Recent Business and Financial UpdatesIn January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND
SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accesse
SALT LAKE CITY, June 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 1,584,159 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.525 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, PolarityTE also agreed to issue and sell to the investor 1,584,159 shares of common stock (or pre-funded warrants in lieu thereof) at the same purchase price
Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical,
SALT LAKE CITY, May 23, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will present at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually. The on-demand session of Mr. Hague and Dr. Sopko's presentation will be available on May 24, 2022 at 7:00am Eastern Time. For more information, visit: https://hcwevents.com/globalconference/ About PolarityTE®PolarityTE, Inc., headquartered in Salt Lake City, Utah,
PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022. Recent Business and Financial UpdatesIn January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND
SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accesse
Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical,
PolarityTE to host conference call and webcast today, May 16, 2022, at 8:30 a.m. ET SALT LAKE CITY, May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the three-month period ended March 31, 2022. Recent Business and Financial UpdatesThus U.S. Food and Drug Administration (FDA) granted PolarityTE's request for SkinTE to be designated as a Regenerative Medicine Advanced Therapy (RMAT). As noted in a press release issued on
SALT LAKE CITY, May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 16, 2022, at approximately 7:30 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on May 16, 2022, at 8:30 a.m. Eastern Time. The conference call can be accessed by calling 1-800-289-0459 with passcode 399675 and referencing "PolarityTE First Quarter 2022 Business Update". A webcast of the conference call can be accessed by using the lin
SALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2022, at approximately 7:30 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on March 30, 2022, at 8:30 a.m. Eastern Time. The conference call can be accessed by calling 1-800-581-5838 (U.S. and Canada) or +44 (0)330 165 3641 (International) with confirmation code 361897 and referencing "PolarityTE Fiscal Year 2021 Earnings Call". A we
SALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the three and nine-month periods ended September 30, 2021. Recent Business and Financial Updates Based on recent informal interactions with FDA regarding certain chemistry, manufacturing, and control (CMC) issues related to the proposed potency assay for SkinTE®, the Company believes that its complete response to FDA's clinical hold correspondence will b
SALT LAKE CITY, Oct. 28, 2021 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended September 30, 2021 by press release on Wednesday, November 10, 2021 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on November 10, 2021 at 8:30 a.m. Eastern Time. The conference call can be accessed by calling 1-800-581-5838 (U.S. and Canada) or +44 (0)330 336 9104 (International) with confirmation code 612545 and referencing "PolarityTE Third Quarter 2021 Earning
PolarityTE to host conference call and webcast today, August 12, 2021, at 4:30 p.m. ET PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the second quarter ended June 30, 2021. Recent Business Updates Submitted an Investigational New Drug application (IND) for SkinTE® on July 23, 2021, for the proposed indication of treatment of chronic cutaneous ulcers Reported SkinTE met primary and secondary endpoints in final analysis from Diabetic Foot Ulcer (DFU) trial Received notice of allowance for additional patent, bringing the Company's total number of allowe
SC 13G/A - POLARITYTE, INC. (0001076682) (Subject)
SC 13G - POLARITYTE, INC. (0001076682) (Subject)
SC 13G - POLARITYTE, INC. (0001076682) (Subject)
SC 13G/A - POLARITYTE, INC. (0001076682) (Subject)
SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE. "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we purs
SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra
8-K - POLARITYTE, INC. (0001076682) (Filer)
NT 10-Q - POLARITYTE, INC. (0001076682) (Filer)
8-K - POLARITYTE, INC. (0001076682) (Filer)
15-12G - POLARITYTE, INC. (0001076682) (Filer)
8-K - POLARITYTE, INC. (0001076682) (Filer)
8-K - POLARITYTE, INC. (0001076682) (Filer)
RW - POLARITYTE, INC. (0001076682) (Filer)
8-K - POLARITYTE, INC. (0001076682) (Filer)
8-K - POLARITYTE, INC. (0001076682) (Filer)
10-Q - POLARITYTE, INC. (0001076682) (Filer)
4 - POLARITYTE, INC. (0001076682) (Issuer)
3 - POLARITYTE, INC. (0001076682) (Issuer)
4 - POLARITYTE, INC. (0001076682) (Issuer)
4 - POLARITYTE, INC. (0001076682) (Issuer)
4 - POLARITYTE, INC. (0001076682) (Issuer)
4 - POLARITYTE, INC. (0001076682) (Issuer)
4 - POLARITYTE, INC. (0001076682) (Issuer)
4 - POLARITYTE, INC. (0001076682) (Issuer)
4/A - POLARITYTE, INC. (0001076682) (Issuer)
4 - POLARITYTE, INC. (0001076682) (Issuer)